PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

GSK, AstraZeneca explore continuous manufacturing in partnership with CPI

  • U.K.-based CPI has set up a collaboration with British big pharmas GlaxoSmithKline and AstraZeneca to develop a continuous wet granulation manufacturing facility for small-scale development of oral solid dosage pharmaceuticals.
  • The facility, based at CPI’s site in northeast England, will go from the blending of raw materials through to granulated end-products, monitored with integrated in-line process analytical technologies (PAT) to improve quality control.
  • To create the facility, CPI is working with a range of suppliers, including GEA Group, Perceptive Engineering, Siemens, Innopharma Labs and Kaiser Optical Systems.

The uptake of continuous manufacturing, a faster and more flexible production process, has lagged in the risk-averse pharma and biotech industries.

Still, a number of the larger companies have dipped their toes in the water, including GlaxoSmithKline, Vertex, Johnson & Johnson and Eli Lilly. In addition to its collaboration with CPI, GlaxoSmithKline is working with the Center for Structured Organic Particulate Systems at Rutgers University to expand its knowledge of continuous manufacturing.

CPI, also known as the Centre for Process Innovation, works with partners to develop better manufacturing processes across a range of industries, including healthcare. It is currently working on a project called PROSPECT CP, which builds on CPI’s existing capabilities.

Kevin Sutcliffe, a principal scientist in global product development at AstraZeneca, said that by having the PAT test bed on the PROSPECT CP platform, the drugmaking industry will be able to use different analytical tools to access data about processes.

“Our collaboration with CPI will complement our own work in AstraZeneca on building models that show the relevance of raw material characteristics and process measurements to product quality,” Sutcliffe added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026